VivoSeq
Immunology

Immunodeficiency

233

Pipeline Programs↗

28

Active Trials↗

52

Companies Involved↗

Immunodeficiency is a highly competitive landscape with 233 programs across 52 companies. The most active players are Vir Biotechnology, Inc., Kenvue Brands, Dexcel Pharma Technologies Ltd.. 18 therapies are approved with 61 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

25/100

Mech. Concentration

14/100

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vir Biotechnology, Inc.

1 program

Phase 1K

Kenvue Brands

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland

5 programs

Phase 2Teva logo

Teva

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical30

Leucovorin Calcium

Eastern Cooperative Oncology Group

Rifampin

Sanofi

Tuberculin Purified Protein Derivative

National Institute of Allergy and Infectious Diseases (NIAID)

Acyclovir

Bp Consulting, Inc

Ganciclovir

Exela Pharma Sciences, LLC.

Phase 145

Cabozantinib

Bristol-Myers Squibb

Lenacapavir

Gilead

Islatravir

Merck & Co.

Doravirine

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Famotidine

Kenvue Brands

Phase 279

Epcoritamab

Genmab

Immune Globulin

CSL Behring

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Maraviroc

GSK

Sirolimus

Prism Pharmaceuticals

Phase 361

Dapagliflozin

AstraZeneca

Cabotegravir

GSK

DARUNAVIR

Wim Janssens

Tenofovir Disoproxil

Gilead

Zidovudine

Bp Consulting, Inc

Approved18

Adenosine

Astellas

Prednisone

Roxane Laboratories

Busulfan

Akero Therapeutics

Nevirapine

Boehringer Ingelheim

R-CHOP

Incyte Biosciences Japan GK

Analysis

Modality Breakdown

92%

Small molecule

231 of 251 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody52%Protein / enzyme31%Peptide31%RNA therapy31%Cell therapy31%Vaccine31%

Small molecule leads; the ring shows all 251 classified programs, each share of the total. Modality classified for 100% of 297 pipeline programs.

Analysis

Trial Status

288

clinical trials

Completed224 · 78%
Active, not recruiting16 · 6%
Terminated15 · 5%
Recruiting12 · 4%
Unknown status9 · 3%
Withdrawn9 · 3%
Other3 · 1%

Clinical Trials

Trial Activity

288 trials

Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)
Recruiting·BBiopharma Plasma LLC·Phase 3·NCT07346859·56 enrolled
Clozapine-related Immunodeficiency in Parkinsons Disease
Recruiting·—·Phase 4·NCT06634641·24 enrolled
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Recruiting·Takeda logoTakeda·N/A·NCT06565078·100 enrolled
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
Recruiting·GSK logoGSK·Phase 3·NCT06134362·3,508 enrolled
Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women
Recruiting·GSK logoGSK·N/A·NCT03564613·250 enrolled
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency
Recruiting·OOn Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.·Phase 3·NCT06954441·50 enrolled
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Recruiting·—·Phase 2·NCT07284641·25 enrolled
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
Recruiting·CSL Behring logoCSL Behring·Phase 4·NCT07076446·8 enrolled
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Recruiting·National Cancer Institute (NCI)·N/A·NCT03300830·280 enrolled
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05027945·54 enrolled
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06819176·50 enrolled
Nice Human Immunodeficiency Virus (HIV) Cohort
Recruiting·CCentre Hospitalier Universitaire de Nice·N/A·NCT03690063·2,000 enrolled
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06891066·150 enrolled
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
Active, not recruiting·GSK logoGSK·Phase 3·NCT03299049·1,049 enrolled
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Active, not recruiting·UUniversity of Calgary·N/A·NCT07015801·1 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)